1. Fig. 2. Exposure of both TCR and CAR antigens diminishes efficacy of CAR8 but not CAR4 cells.
Exposure of both TCR and CAR antigens diminishes efficacy of CAR8 but not CAR4 cells. (A) IL-2 and IFN-γ production by HY-CAR4 and HY-CAR8 cells after 10 hours of incubation with CD19KO female splenocytes (CD19−/HY−), CD19KO male splenocytes (CD19−/HY+), or wild-type (WT) female splenocytes (CD19+/HY−) (**P < 0.001, ****P < ). (B) CD107a expression (red) and isotype control (gray) on HY-CAR T cells after 4 hours of incubation with CD19+ E2aPbx ALL. (C) HY-CAR4 or HY-CAR8 cells were administered on day 4 to E2aPbx-bearing syngeneic male (HY+) and female (HY−) recipients. (D) Survival of female (TCR antigen−) and male (TCR antigen+) recipients after treatment with 1 × 106 HY-specific CAR4 or CAR8 cells (n = 5 per group; **P < 0.01). (E) Leukemia burden in the bone marrow 7 days after infusion of mice treated with HY-CAR4 or HY-CAR8 cells (****P < 0.001, one-way ANOVA performed for all comparisons and log-rank Mantel-Cox test for survival analysis).
Yinmeng Yang et al., Sci Transl Med 2017;9:eaag1209
Published by AAAS